In addition, patients with hyponatremia and squamous cell carcinoma group had a poor prognosis (P<0.05).<h4>Conclusions</h4>The interpretable model constructed in this study provides a new approach for the prediction of EGFR mutation status in NSCLC patients, which provides a scientific basis for the diagnosis and treatment of patients who cannot undergo genetic testing. This evidence concerns the gene EGFR and squamous cell carcinoma.